We are excited about the data and plan to submit the data for publication and peer reviewed medical journal in the near term.

$AVXL Australia trial data meets the gold standard.

$AVXL - Alz Topline Data was solid ..

Efficacy is likey overwhelming after seeing 👀 data details!

$AVXL I am extremely bullish on the data .. the FDA can ask any sorts of questions

I'm looking forward to seeing the long term AD data on ANVS and have the feeling it's going to end up being the best in class AD treatment as well.

Now DATA met expectations.

Also clint said every time Blarcamesine data comes back it looks better and better. .

Anavex has significant 4 years of ph2/3 safety data with safety back to 2013 for Blarcamesine .. anavex has full 3 endpoint trial and a placebo .. it's obvious Anavex wins!!

So I think the data so far was encouraging,

$HEPA let’s see it positive… NO Sellers ‼️ what will happen if volume comes in after data readouts 🙄🤭

(good addition to the data we already have on pharmacokinetics.)

$HEPA < 1/20th the price of Akero (2bn+ cap) and Madrigal (4bn+), with likely better NASH data, and much broader set of other applications (e.g. combos, PD-1, etc)

Excited to look into more data that will undoubtedly come the coming months.

The 28 day data also documented Rencofilstat’s amazingly fast & potent efficacy at reduction of fibrosis that in just 4 short weeks exceeded that of Madrigal’s 12 month hospitalization IV dosage results for their drug used in NASH.

If the market feels the data is good, the market will let us know and we are golden.

The market price is not reflecting the true enterprise value, which is giving folks an incredible buying opportunity as we head into a long, long series of extraordinary good news releases confirming the data gathered from 300+ clinical trials to date.

And Rencofilstat has a growing body of data results showing that with certain combo drugs Rencofilstat transforms into an incredible Super Drug of dramatically increased efficacy!!! 🎉🎉🎉

The article on the positive data from Rencofilstat highlighted by the elucidation of the data from just 28 days of dosing in the 2021 AMBITION Trial is just astonishing.

ATNM just published very good data from their P3 trail which is great news for Acute myeloid leukemia patients.

but this time they look way more stronger and aggressive with the data.

Translate the data on this (today's sec release) Seems VERY positive and with a cash run into 2024 on worst case basis.

Watching $TGTX PDUFA data in the coming days and congrats to those who held on to $VRNA big win today.

up 290% After Positive Resmetirom Liver Treatment Phase3 Trial data.